Publications by authors named "Tai-Ran Chen"
[Efficacy and Safety of Flumatinib and Imatinib as First-line Treatments for Newly-diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Real-world Study].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Objective: To compare the efficacy and safety of flumatinib (FM) and imatinib (IM) as first-line treatment in newly-diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) in real world.
Methods: A total of 84 newly-diagnosed CP-CML patients in our center from December 2019 to December 2022 were retrospectively analyzed. Among them, 32 cases received FM as first-line treatment, and 52 cases received IM.
Article Synopsis
- The study aims to compare two predictive models (CRP to ALB ratio and Glasgow prognostic score) for assessing prognosis in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL).
- Data from 111 DLBCL patients treated with R-CHOP chemotherapy were analyzed to evaluate the predictive value of the CRP to ALB ratio (CAR) on patient survival and disease progression.
- Results showed that a higher CAR was linked to more clinical risk factors, and patients with lower CAR scores had significantly better overall and complete response rates compared to those with higher scores.